Radiation oncology company Accuray has received CE mark approval for its new Radixact system, which will allow faster delivery of precise treatment to a range of cancer patients across the European market.

The Radixact platform features three new technologies that include Radixact Treatment Delivery System, Accuray Precision Treatment Planning System, iDMS Data Management System.

With enhanced linear accelerator, MVCT imaging and helical treatment delivery features, the system allows clinicians to apply conformal and homogeneous dose distributions to any target volume, while precisely sparing normal healthy tissue during each treatment fraction.  

Accuray precision treatment planning system is a mid-course decision-making that enable clinicians to adapt delivery as per changes in tumor size, shape and location

The iDMS data management system allows to manage patient data across multiple Radixact systems and clinics from a single point of control.

In June, the company also received FDA 510(k) clearance for the Radixact platform, which includes next generation hardware and software solutions

Accuray president and CEO Joshua Levine said: “Radixact System availability in the EU is a critical component of our commercial launch strategy for this innovative platform.

“We have shipped the first commercially released Radixact System to a site in the U.S. and expect our first EU shipment during our Fiscal Q1 2017.

“The system is a key driver of our short- and long-term growth outlook, as well as our ability to achieve sustainable profitability, and we are excited about the reception the system is receiving in the marketplace.”